Neuroendocrine Prostate Cancer Market Report 2026

The neuroendocrine prostate cancer market size has grown strongly in recent years. It will grow from $1.05 billion in 2025 to $1.14 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to rise in prostate cancer diagnosis, long term hormone therapy resistance, expansion of oncology drug pipelines, growth of molecular pathology testing, increased cancer center specialization.

The neuroendocrine prostate cancer market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growth of precision oncology adoption, rising biomarker based treatment, expansion of targeted therapies, increased rare cancer research funding, broader genomic testing use. Major trends in the forecast period include biomarker driven patient stratification, combination oncology therapy protocols, advanced molecular diagnostic testing, rare cancer clinical trial expansion, targeted radiopharmaceutical approaches.

The growing prevalence of prostate cancer is expected to drive the growth of the neuroendocrine prostate cancer market in the coming years. Prostate cancer is a malignant tumor that develops in the prostate gland, primarily affecting men over 50 years of age. The prevalence of prostate cancer is increasing mainly due to the expanding aging male population, as advancing age is a key risk factor for disease development. The prevalence of prostate cancer supports the growth of neuroendocrine prostate cancer by enlarging the overall patient pool, increasing long-term exposure to androgen-deprivation therapies, and thereby raising the likelihood of treatment-induced neuroendocrine differentiation in advanced and castration-resistant stages of the disease. For instance, in January 2025, the Centers for Disease Control and Prevention (CDC), a U.S. federal public health agency, reported that in 2023 there were 255,395 new cases of prostate cancer diagnosed in the United States, with 33,881 men succumbing to the disease. Therefore, the increasing prevalence of prostate cancer is driving the growth of the neuroendocrine prostate cancer market.

Organizations operating in the neuroendocrine prostate cancer market are focusing on developing innovative drugs such as immune-modulating small-molecule therapies to enhance immune response and improve patient outcomes. Immune-modulating small-molecule therapies are orally administered compounds that stimulate the body’s innate immune system to recognize and attack cancer cells, helping overcome resistance to traditional treatments such as hormone therapy or chemotherapy by enhancing the anti-tumor immune response. For example, in February 2024, BioXcel Therapeutics, a US-based clinical-stage biopharmaceutical company, received Fast Track Designation from the U.S. Food and Drug Administration for BXCL701, an immune-modulating small-molecule therapy for neuroendocrine prostate cancer. BXCL701 is designed to activate the NLRP3 inflammasome, increase cytokine release, and prime the immune system to target tumor cells, offering a novel approach that complements immune checkpoint inhibitors. The Fast Track Designation is expected to accelerate the clinical development and regulatory review of BXCL701, reflecting its potential to address significant unmet medical needs in aggressive and treatment-resistant prostate cancer.

In March 2024, Merck & Co. Inc., a US-based healthcare and biopharmaceutical company, acquired Harpoon Therapeutics, Inc. for an undisclosed sum. This acquisition enables Merck & Co., Inc. to expand and diversify its oncology pipeline by strengthening its portfolio of innovative T-cell engagers for advanced cancers. Harpoon Therapeutics Inc. is a US-based biotechnology company that develops pioneering T-cell engager therapies for cancers including small cell lung cancer, neuroendocrine prostate cancer, and multiple myeloma.

Major companies operating in the neuroendocrine prostate cancer market are Novartis AG, Amgen Inc., Phanes Therapeutics Inc., and BioXcel Therapeutics Inc.

Tariffs on oncology drugs, biologics inputs, and diagnostic reagents are impacting the neuroendocrine prostate cancer market by increasing treatment and testing costs. Imported chemotherapeutic agents and specialized diagnostic kits are the most affected segments. Countries that rely heavily on imported oncology supplies face higher therapy pricing and budget pressure. These cost increases can affect access in cost sensitive healthcare systems. At the same time, tariffs are encouraging domestic oncology drug manufacturing and local diagnostic kit production.

The neuroendocrine prostate cancer market research report is one of a series of new reports that provides neuroendocrine prostate cancer market statistics, including neuroendocrine prostate cancer industry global market size, regional shares, competitors with a neuroendocrine prostate cancer market share, detailed neuroendocrine prostate cancer market segments, market trends and opportunities, and any further data you may need to thrive in the neuroendocrine prostate cancer industry. This neuroendocrine prostate cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neuroendocrine prostate cancer is a rare and aggressive prostate cancer subtype marked by neuroendocrine cells that influence tumor growth and resistance to conventional treatments. This condition can occur de novo or arise after long-term androgen deprivation therapy in prostate cancer patients. Treatment options include chemotherapy, targeted therapy, immunotherapy, and supportive care to manage symptoms and improve patient outcomes.

The primary types of neuroendocrine prostate cancer treatment include chemotherapy and hormonal therapy. Chemotherapy refers to the administration of cytotoxic medications to destroy or suppress the growth of cancerous cells within the prostate. These treatments are also available as therapeutic options including immunotherapy and targeted therapy. They are applied across disease stages such as localized disease, advanced disease, and metastatic disease, and are utilized by end users including hospitals, oncology specialty clinics, and cancer research institutes.

The neuroendocrine prostate cancer market consists of revenues earned by entities by providing services such as advanced diagnostic and pathological testing, molecular and biomarker analysis, oncological consultations, personalized treatment planning, and administration and monitoring of systemic therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroendocrine prostate cancer market also includes sales of chemotherapeutic agents, hormone therapy-resistant drugs, radiopharmaceuticals, diagnostic kits and biomarker assays, and supportive oncology medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.